Novel food authorization timelines: three data points shaping EFSA approvals
A nine-month EFSA assessment target can look like a workable launch assumption. The available application data point to a longer and less predictable process.
In a 2025 analysis of 292 novel food applications submitted between 2018 and 2024, the average time from dossier submission to publication of EFSA’s scientific opinion was 937 days, or about 31 months. That figure still stops short of final EU authorisation.
The distinction matters for manufacturers planning ingredient sourcing, customer commitments and market entry. The novel food authorization timeline is not one regulatory clock: it includes administrative validation, scientific assessment, possible pauses for information requests, publication of EFSA’s opinion and a subsequent decision by the European Commission and Member States. Treating the assessment target as an end-to-end deadline can leave a compliant product commercially stranded.
The dataset shows a long and variable front end
The 2025 study examined 292 applications submitted to EFSA between 2018 and 2024. Its status snapshot was dated 4 October 2024. The reported timings describe analyzed applications and particular stages, not a guaranteed schedule for a new dossier.
The first substantial delay can occur before scientific evaluation begins. For a set of 194 applications, the combined validation-check phase, measured from submission to the start of scientific evaluation, averaged 299 days, with a standard deviation of 218 days. The observed range was 20 to 1,635 days. Two applications identified as outliers were excluded from this phase analysis.
That spread is operationally significant. A mean near ten months may suggest a planning buffer; the range shows why the mean cannot serve as a filing-to-review commitment. The validation and suitability stage is also not merely a queue. It is where completeness and fit for evaluation are considered, so gaps in the dossier can affect when the scientific work starts.
For manufacturers, a long pre-assessment interval creates a particular kind of uncertainty: the ingredient may not yet have reached the stage that people commonly mean when they say EFSA is reviewing it. Internal project reporting should distinguish submission, validation progress and the start of scientific evaluation. Otherwise, a delayed validation can be misread as a slow scientific assessment, obscuring where a corrective action may be needed.
The study’s figures also require careful comparison. The 299-day average is based on 194 applications, while the scientific-evaluation average comes from 88 applications with available validation dates. These are different analysis sets. They should not be added together as if they describe one uniform group moving through every stage on a predictable schedule.
The first planning risk may arrive before the scientific assessment clock starts.
Scientific evaluation: nine months is a target, not an end-to-end forecast
EFSA states that scientific assessment should take nine months when an application contains all necessary information. That is the formal period for the assessment under the stated condition. It is not a promise that the entire authorisation process will finish in nine months, and it does not override the observed timeline in the application analysis.
For 88 applications with available validation dates, the study reported an average scientific evaluation duration of 629 days, or approximately 20.7 months. The standard deviation was 338 days, and the range ran from 179 to 1,714 days. The difference between the formal assessment period and the observed average should not be read as evidence of one universal cause. The data establish the elapsed times in this cohort; they do not provide a single explanation applicable to every file.
One known mechanism is the clock-stop. EFSA may pause the assessment while it waits for additional information. In practice, that means elapsed calendar time can exceed the stated nine-month assessment period without the clock running continuously. A dossier that appears complete at submission may still encounter questions requiring new evidence or clarification, and the time needed to prepare and deliver a response can affect the overall schedule.
This is where the commercial investigation becomes a dossier-management problem. If the ingredient depends on a specific manufacturing process, source material or intended use, the supporting evidence needs to be coherent across those elements. A request for additional information can have consequences beyond the regulatory team: technical staff may need to retrieve process records, quality teams may need to reconcile specifications, and procurement may need to preserve traceability across lots or suppliers. The supplied timeline study does not quantify those internal costs, but its wide observed range makes it imprudent to plan as if the assessment period were fixed.
A cautious internal schedule should therefore separate at least three items: the formal EFSA assessment period, the time required to resolve potential information requests, and the wider elapsed time observed in the study. The 629-day mean is useful as evidence that real-world scientific evaluation has taken substantially longer than nine months in this analyzed set. It is not a forecast for a particular novel ingredient, nor a service-level commitment from EFSA.
The key figures are best read with their boundaries intact:
| Stage or interval | Reported timing | What the figure covers |
|---|---|---|
| Validation and suitability checks | 299 ± 218 days; range 20–1,635 days | 194 applications, with two identified outliers excluded |
| EFSA scientific evaluation | 629 ± 338 days; range 179–1,714 days | 88 applications with available validation dates |
| Panel vote to publication | 48 ± 16 days; range 26–107 days | 91 published EFSA outputs |
| Submission to publication of EFSA opinion | 937 ± 436 days; range 330–2,314 days | Analyzed applications through publication, not final authorisation |
| Formal scientific-assessment period | Nine months when the application contains all necessary information | EFSA’s stated assessment period; the clock may stop for information requests |
These metrics should not be combined into a single benchmark without checking their denominators and endpoints. The study reports separate groups for different intervals, and the 937-day figure is an overall submission-to-opinion-publication measure for its analyzed cohort. It is not a simple sum of every stage average in the table.
Publication adds time, but does not settle market access
After the scientific panel votes, publication is a further interval. For 91 published outputs, the study found an average of 48 days between the panel vote and publication, with a standard deviation of 16 days and a range of 26 to 107 days.
This is smaller than the earlier phases, but it still matters when a business is coordinating regulatory communications, customer onboarding or production planning. A panel vote and a publicly available opinion are different milestones. Operational dashboards that record only the vote date can therefore show progress before the document needed for external interpretation is published.
More importantly, publication of EFSA’s opinion is not the end of the EU process. EFSA provides the scientific risk assessment. The European Commission and EU Member States decide whether to authorise the novel food and which uses may be permitted. A positive EFSA opinion does not itself grant market authorisation.
The study’s mean of 937 days, approximately 31 months, runs from dossier submission to publication of EFSA’s opinion. Its endpoint does not include the subsequent Commission authorisation decision. The available facts do not establish a single current average for the full submission-to-final-authorisation pathway, so it would be misleading to label 937 days the full approval duration.
This boundary has immediate implications for launch planning. A team should avoid treating scientific acceptance as equivalent to a cleared commercial route. The final decision determines whether the ingredient can be placed on the market and within what permitted uses. Product specifications, customer contracts and supply commitments may all depend on that distinction.
If a commercial plan assumes a specific use, dose or food category, the regulatory team should map that intended use to the eventual authorisation scope before the business commits to unrestricted supply. If the contemplated use falls outside the permitted conditions, a favourable scientific opinion alone does not resolve the compliance gap.
What manufacturers can do with the metrics
The data are not a rejection-rate study. They do not provide a basis for estimating the probability that a novel ingredient will be approved or rejected, and they should not be used as a proxy for the quality of a particular dossier. They do provide a more grounded way to structure timelines and escalation points.
For a manufacturer assessing a prospective ingredient, the practical sequence is:
1. Set the commercial date against the full pathway. Keep submission, validation, start of scientific evaluation, panel vote, publication and Commission decision as separate milestones. Do not use the nine-month assessment period as the launch date.
2. Build a response plan for information requests. Identify who owns process, composition, safety and traceability records before a request arrives. The EFSA clock may stop while additional information is awaited, so internal response readiness can affect elapsed time.
3. Keep supply assumptions conditional. If the ingredient is sourced from a narrow supplier base or tied to a particular production process, avoid commitments that assume authorisation will cover every planned use. Link purchase and customer milestones to defined regulatory milestones.
4. Track the scope of the eventual decision. A scientific opinion and a market authorisation are separate steps, and the Commission decision governs authorised uses. Regulatory clearance should be checked against the product and application actually intended.
5. Use cohort averages as context, not a forecast. The study’s averages are observations from particular application sets. They are not a legal deadline, an individual-case prediction or a universal benchmark for every novel food submission.
These steps are especially relevant for ingredients whose commercial value depends on reaching a market by a fixed season or customer launch window. The data do not show how often such plans fail, but they do show that observed processing times vary widely and that the main reported endpoint precedes the final EU authorisation decision.
The terminology also matters in cross-functional reporting. “EFSA review complete” should mean that the scientific opinion has reached its defined endpoint, not that the ingredient is authorised for sale. “Approval timeline” should identify whether it measures to opinion publication or to the Commission’s decision. Without that precision, sales, regulatory and supply-chain teams can work from different assumptions while using the same label.
For businesses comparing jurisdictions, these figures should remain specific to the EU novel food pathway. The supplied analysis does not establish equivalent timelines for FDA ingredient approvals, GRAS notifications, food additive compliance reviews or other regulatory routes. Applying the EU cohort averages to those systems would create false comparability.
The operational read-through
The clearest conclusion from the 2025 analysis is not a new deadline. It is a need to plan around stages and uncertainty. Validation and suitability checks averaged 299 days in the analyzed set. Scientific evaluation averaged 629 days for applications with available dates. Publication followed the panel vote by an average of 48 days. Submission to publication of EFSA’s opinion averaged 937 days, but that measure excluded the subsequent authorisation decision.
For manufacturers, the next operational step is to revise project timelines so that the nine-month assessment period sits within a wider, stage-based plan. Regulatory and supply-chain owners should confirm the intended use, assign responsibility for information-request responses, preserve supporting traceability records and keep commercial commitments conditional on the actual authorisation scope.
That approach does not eliminate delay. It makes the liability and continuity risks visible before they reach customers, production schedules or inventory decisions.